Detalhe da pesquisa
1.
A Somatically Acquired Enhancer of the Androgen Receptor Is a Noncoding Driver in Advanced Prostate Cancer.
Cell
; 174(2): 422-432.e13, 2018 07 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-29909987
2.
Integrative eQTL-based analyses reveal the biology of breast cancer risk loci.
Cell
; 152(3): 633-41, 2013 Jan 31.
Artigo
em Inglês
| MEDLINE | ID: mdl-23374354
3.
Integrative multi-omics analyses to identify the genetic and functional mechanisms underlying ovarian cancer risk regions.
Am J Hum Genet
; 2024 May 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-38723632
4.
Allele-specific epigenetic activity in prostate cancer and normal prostate tissue implicates prostate cancer risk mechanisms.
Am J Hum Genet
; 108(11): 2071-2085, 2021 11 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-34699744
5.
H3K27ac HiChIP in prostate cell lines identifies risk genes for prostate cancer susceptibility.
Am J Hum Genet
; 108(12): 2284-2300, 2021 12 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-34822763
6.
Ovarian Cancer Risk Variants Are Enriched in Histotype-Specific Enhancers and Disrupt Transcription Factor Binding Sites.
Am J Hum Genet
; 107(4): 622-635, 2020 10 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32946763
7.
Increased chromatin accessibility drives transition to androgen receptor splice variant dependence in castration-resistant prostate cancer.
bioRxiv
; 2024 Jan 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-38260576
8.
The PENGUIN approach to reconstruct protein interactions at enhancer-promoter regions and its application to prostate cancer.
Nat Commun
; 14(1): 8084, 2023 Dec 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-38057321
9.
Landscape of prostate-specific membrane antigen heterogeneity and regulation in AR-positive and AR-negative metastatic prostate cancer.
Nat Cancer
; 4(5): 699-715, 2023 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-37038004
10.
A biallelic multiple nucleotide length polymorphism explains functional causality at 5p15.33 prostate cancer risk locus.
Nat Commun
; 14(1): 5118, 2023 08 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-37612286
11.
Epigenomic charting and functional annotation of risk loci in renal cell carcinoma.
Nat Commun
; 14(1): 346, 2023 01 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-36681680
12.
Liquid biopsy epigenomic profiling for cancer subtyping.
Nat Med
; 29(11): 2737-2741, 2023 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-37865722
13.
A multi-level investigation of the genetic relationship between endometriosis and ovarian cancer histotypes.
Cell Rep Med
; 3(3): 100542, 2022 03 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-35492879
14.
Genetic determinants of chromatin reveal prostate cancer risk mediated by context-dependent gene regulation.
Nat Genet
; 54(9): 1364-1375, 2022 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-36071171
15.
Response to supraphysiological testosterone is predicted by a distinct androgen receptor cistrome.
JCI Insight
; 7(10)2022 05 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-35603787
16.
Extensive androgen receptor enhancer heterogeneity in primary prostate cancers underlies transcriptional diversity and metastatic potential.
Nat Commun
; 13(1): 7367, 2022 11 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-36450752
17.
Detecting Neuroendocrine Prostate Cancer Through Tissue-Informed Cell-Free DNA Methylation Analysis.
Clin Cancer Res
; 28(5): 928-938, 2022 Mar 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34907080
18.
A genome-scale CRISPR screen reveals PRMT1 as a critical regulator of androgen receptor signaling in prostate cancer.
Cell Rep
; 38(8): 110417, 2022 02 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-35196489
19.
CREB5 reprograms FOXA1 nuclear interactions to promote resistance to androgen receptor-targeting therapies.
Elife
; 112022 05 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-35550030
20.
MYC drives aggressive prostate cancer by disrupting transcriptional pause release at androgen receptor targets.
Nat Commun
; 13(1): 2559, 2022 05 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-35562350